Qisda Corp
TWSE:2352
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.05
41.5621
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Qisda Corp
Qisda Corp., originally emerging from BenQ Corporation, has steadily charted its course within the competitive landscape of global technology solutions. Founded in Taiwan, Qisda began as a hardware manufacturer and burgeoned into a multifaceted company with interests spanning from IT products to healthcare solutions. The company’s DNA showcases its relentless pursuit of innovation alongside its commitment to delivering high-value products. By leveraging its extensive R&D capabilities, Qisda strives to integrate cutting-edge designs in its product offerings, ranging from monitors and projectors to sophisticated IoT solutions and medical devices. As the technology sphere evolves, Qisda has adeptly diversified its business portfolio, a strategy which secures its role as a key player in various technology-driven industries.
The crux of Qisda's business model revolves around manufacturing and design services, underpinning its prominence in the OEM and ODM sectors. The company generates revenue by offering its high-tech design and manufacturing expertise to numerous global brands, creating a foundation of trust and quality through its expansive production facilities and a diversified client base. Moreover, Qisda’s engagement in the medical sector, via its subsidiary BenQ Medical Technology, is not just a remarkable expansion but a strategic pivot towards a nascent and profitable frontier. By aligning its technological prowess with healthcare innovation, Qisda is not only fortifying its revenue streams but also enhancing its resilience against market fluctuations, ensuring long-term growth and sustainability.
Qisda Corp., originally emerging from BenQ Corporation, has steadily charted its course within the competitive landscape of global technology solutions. Founded in Taiwan, Qisda began as a hardware manufacturer and burgeoned into a multifaceted company with interests spanning from IT products to healthcare solutions. The company’s DNA showcases its relentless pursuit of innovation alongside its commitment to delivering high-value products. By leveraging its extensive R&D capabilities, Qisda strives to integrate cutting-edge designs in its product offerings, ranging from monitors and projectors to sophisticated IoT solutions and medical devices. As the technology sphere evolves, Qisda has adeptly diversified its business portfolio, a strategy which secures its role as a key player in various technology-driven industries.
The crux of Qisda's business model revolves around manufacturing and design services, underpinning its prominence in the OEM and ODM sectors. The company generates revenue by offering its high-tech design and manufacturing expertise to numerous global brands, creating a foundation of trust and quality through its expansive production facilities and a diversified client base. Moreover, Qisda’s engagement in the medical sector, via its subsidiary BenQ Medical Technology, is not just a remarkable expansion but a strategic pivot towards a nascent and profitable frontier. By aligning its technological prowess with healthcare innovation, Qisda is not only fortifying its revenue streams but also enhancing its resilience against market fluctuations, ensuring long-term growth and sustainability.
Quarterly Growth: Qisda posted third quarter revenue of NTD 50.8 billion, up 2% quarter-over-quarter, with profit and operating income also rising sequentially.
Margins: Gross margin hit 16.8%, the highest in 20 years, and has stayed above 16% for six consecutive quarters.
Segment Trends: IT Original business and Medical both showed revenue growth; NCG faced continued inventory digestion, but expects a rebound next year.
Fourth Quarter Outlook: Management expects the fourth quarter to outperform the third in both revenue and profit, with growth seen in most business groups.
Medical Expansion: The Norbel Baby (Ding Ding Drug Store) acquisition is progressing, with strategic integration planned for next year. Medical group revenue is not expected to hit NTD 30 billion in 2024 but should exceed that in 2025.
AI & Technology: The company is focusing on AIoT and smart solutions, with investments in edge computing, AI servers, and robotics driving future growth.
Geopolitical Preparedness: Management highlighted supply chain resilience and manufacturing readiness in Taiwan, China, and Vietnam to adapt to global uncertainty.
Sustainability Targets: Qisda reaffirmed its carbon reduction goals, aiming for 30% reduction by 2030 and net zero by 2050.